NCT07287917 2026-03-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
18 trialsNCT02523014 2026-03-04
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT07294677 2026-03-04
CAVALRY
University of Chicago
Phase 1/2 Recruiting
NCT06982521 2026-03-03
ReDiscover-2
Relay Therapeutics, Inc.
Phase 3 Recruiting
NCT07088913 2026-03-03
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT07281833 2026-02-27
CAPIcorn
West German Study Group
Phase 3 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT07343960 2026-02-24
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
Phase 1 Recruiting
NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
NCT03742102 2026-02-02
BEGONIA
AstraZeneca
Phase 1/2 Active not recruiting
NCT04493853 2026-01-20
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06635447 2026-01-13
CAPItrue
AstraZeneca
Phase 3 Recruiting
NCT06764186 2026-01-13
CAPItana
AstraZeneca
Phase 3 Active not recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06613516 2025-12-24
CaptAin
Imperial College London
Phase 2 Withdrawn
NCT03997123 2025-12-22
CAPItello-290
AstraZeneca
Phase 3 Active not recruiting